Your browser doesn't support javascript.
loading
Metabolic syndrome is independently associated with improved overall survival to first-line therapy with immune checkpoint inhibitors in non-small cell lung cancer.
Bou Zerdan, Maroun; Ashok Kumar, Prashanth; Barrios, Dulce M; Glidden, Alanna; Nasr, Dayana; Niforatos, Stephanie; Ghelani, Ghanshyam; Leibovitch, Jennifer; Nasr, Sandy; Kc, Binod; Ombada, Mulham; Khokhar, Farzam; Poudyal, Bhavya; Bhandari, Jenish; Shahnawaz, Myera; Graziano, Stephen; Lim, Seah H.
Afiliação
  • Bou Zerdan M; Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
  • Ashok Kumar P; Division of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
  • Barrios DM; Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
  • Glidden A; Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
  • Nasr D; Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
  • Niforatos S; Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
  • Ghelani G; Division of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
  • Leibovitch J; Division of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
  • Nasr S; Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
  • Kc B; Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
  • Ombada M; Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
  • Khokhar F; Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
  • Poudyal B; Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
  • Bhandari J; Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
  • Shahnawaz M; Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
  • Graziano S; Division of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
  • Lim SH; Division of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
Front Oncol ; 13: 1134824, 2023.
Article em En | MEDLINE | ID: mdl-37251929
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article